[Mode of action and clinical evaluation of platelet aggregation inhibitors].
D001241:Aspirin / Q000494:pharmacology; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D004176:Dipyridamole / Q000494:pharmacology; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology; D009203:Myocardial Infarction / Q000517:prevention & control; D010974:Platelet Aggregation / Q000187:drug effects*; D013442:Sulfinpyrazone / Q000494:pharmacology; D013988:Ticlopidine / Q000494:pharmacology
D004176:Dipyridamole; D007650:Ketanserin; D013988:Ticlopidine; D001241:Aspirin; D013442:Sulfinpyrazone
Mode d'action et évaluation clinique des antiagrégants plaquettaires.